Drugs / Bemalenograstim alfa
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06134765 | Nov 2023 → Oct 2024 | colorectal cancer, malignant pancreatic neoplasm | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bemalenograstim alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06134765 ↗ |
| Route | Subcutaneous | “Subcutaneous injection of Bemalenograstim alfa 20mg/ time 24-48h after each cycle of chemotherapy.” NCT06134765 ↗ |